Navigation Links
Sunrise Provides Update on HCN Transaction
Date:10/31/2008

MCLEAN, Va., Oct. 31 /PRNewswire-FirstCall/ -- Sunrise Senior Living, Inc. (NYSE: SRZ) today announced that the previously disclosed transaction between an affiliate of Arcapita Inc. and Health Care REIT (HCN), under which HCN would have purchased a 90% interest in a venture owning 29 senior housing properties managed by Sunrise, has been terminated. The termination of the transaction will have no impact on Sunrise's 10% interest in the venture. Sunrise will continue to manage the properties under long term contracts expiring in 2025. Due to the termination of the HCN transaction, Sunrise will not receive the estimated cash distributions of approximately $50 million to $60 million and will not realize the estimated gain of approximately $41 million to $51 million in the fourth quarter of 2008 that Sunrise anticipated in connection with this transaction.

"We understand Health Care REIT's decision not to complete this transaction was due to current market conditions," said Mark Ordan, Sunrise's chief investment and administrative officer and CEO-designate. "We are pleased to continue owning 10% of these properties and to continue managing them for our capital partner. We have had a long and successful relationship with Arcapita and we look forward to continuing to partner with them on future projects. These are excellent communities in large and attractive markets and they are performing well.

"Given the extreme uncertainty of the current capital markets, in order to maintain as much financial flexibility as possible, we are working closely with our banks and other sources of capital to provide additional sources of liquidity. Although there can be no assurance as to these or other prospective matters in the current turbulent e
'/>"/>

SOURCE Sunrise Senior Living, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sunrise to Host Conference Call and Webcast to Discuss the Companys Financial Results for the Third Quarter 2008
2. Sunrise Senior Living Appoints Glyn Aeppel and David Fuente to its Board
3. Sunrise Files 2007 Form 10-K
4. Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data
5. Sunrise Senior Living Founder and CEO to Become Chairman
6. Sunrise to Present at Jefferies 2nd Annual Healthcare Conference
7. Sunrise to Present at Bank of America Healthcare Conference
8. Hawks Cay Hosts Redbone Sunrise/Sunset Tarpon Tournament
9. Sunrise Files 2006 Form 10-K
10. Sunrise Senior Living Names Mark Ordan Chief Investment and Administrative Officer
11. Sunrise Announces NYSE Deadline Extended
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 LDM Global ... eDiscovery pricing model that is simplified and predictable with ... size. As a leading international provider of legal ... agencies it has become glaringly apparent that both the ... ballooning eDiscovery budgets and the complex pricing structure that ...
(Date:7/31/2014)... 2014 (HealthDay News) -- With the World Health Organization ... Ebola outbreak has risen to 729, the U.S. ... a travel warning for,the region. The "Level 3 ... affected countries -- Guinea, Liberia and Sierra Leone -- ... is worsening in West Africa," CDC Director Dr. Tom ...
(Date:7/31/2014)... Ontario (PRWEB) July 31, 2014 Setting goals ... seen on blogs on successful tips to weight loss. Fitness ... goals for over 8 years, and has worked with 6000 ... trainers. “We have had the chance to monitor why customers ... stop exercising, how long they stick to their program, whether ...
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 The VitalSleep anti ... lower jaw forward to help open a snorers airway to quiet ... anti-snoring remedy helped her relationship with her husband by allowing ... a 46 years old. My snoring began about 15 years ago ... husband and children could not sleep and had to head downstairs ...
(Date:7/31/2014)... New York (PRWEB) July 31, 2014 ... grow, as Bernstein Liebhard LLP notes that Johnson ... it plans to voluntarily remove its power morcellators ... a report from Bloomberg.com, the company said it ... benefits associated with the devices remain uncertain.* , ...
Breaking Medicine News(10 mins):Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... quit, particularly for some teens and African-Americans, who have ... by a team of researchers. , Recent studies have ... have a lower quit rate than comparable smokers of ... suggested in the report is that the menthol effect ...
... ARBOR, Mich. Black people with early stage liver cancer ... disease, according to a new study from the University of ... percent of white liver cancer patients were alive but only ... patients were. Median survival times ranged from 10 months for ...
... surgery for upper airway and digestive track malignant tumors ... based on patient function and survival, according to University ... squamous cell carcinomas account for about 4 percent of ... Currently the standard minimally invasive surgery for these tumors ...
... Reporter , MONDAY, Dec. 20 (HealthDay News) -- Most trauma ... make it to their final destination within the two hours ... patients did make it within the time window, ... study in the December issue of the Archives of ...
... By Steven Reinberg HealthDay Reporter , MONDAY, Dec. ... Americans, a new study shows, despite reported links to an ... "spray-on" tans. In fact, about one in every five ... use indoor tanning, University of Minnesota researchers report. "Tanning ...
... -- Most head and neck cancer patients can speak ... but several factors may be associated with poor outcomes, ... who were assessed nearly three years after they were ... cancer. The U.S. researchers gave a speaking score ...
Cached Medicine News:Health News:Quitting menthol cigarettes may be harder for some smokers 2Health News:Blacks with liver cancer more likely to die, study finds 2Health News:Robotic surgery for head and neck cancer shows promise 2Health News:Most Trauma Patients Not Transferred Within Mandated Time Frame in Illinois 2Health News:Most Trauma Patients Not Transferred Within Mandated Time Frame in Illinois 3Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 2Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 3Health News:Speech, Swallowing Usually OK After Head & Neck Cancer Therapy 2
(Date:7/31/2014)... -- Cryoport, Inc. (OTCBB: CYRX) today announced financial results ... Recent Operating Highlights , Achieved ... month period ended June 30, 2014 compared to the ... further expand Cryoport,s global reach using the ,powered by ... Immudex, an immunotherapy and vaccine development services company, to ...
(Date:7/31/2014)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... 2014, on Thursday, August 7, 2014 before markets open. ... and conference call at 8:00 a.m. Eastern time (5:00 ... the call and webcast to discuss financial results and ... by calling (800) 708-4540 (domestic) or (847) 619-6397 (international), ...
(Date:7/31/2014)...  Celsion Corporation (NASDAQ: CLSN ) announced ... to discuss its second quarter 2014 financial results at ... participate in the call, interested parties may dial 1-800-533-7954 ... and ask for the Celsion Corporation Second Quarter 2014 ... before the call is scheduled to begin. The call ...
Breaking Medicine Technology:Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Celsion Corporation to Hold Second Quarter 2014 Financial Results 2
... PARK, N.J., Jan. 25, 2012  Shionogi Inc., the U.S.-based ... results from two studies published online today in the ... first study, a randomized, double-blind, placebo-controlled phase III trial ... with problem drooling due to neurologic conditions demonstrated a ...
...  Amorcyte, LLC, a NeoStem, Inc. company (NYSE Amex: ... of the first patient in the Amorcyte PreSERVE ... study is a multicenter, randomized, double-blind, placebo-controlled clinical ... infarct-related artery infusion of AMR-001, an autologous bone ...
Cached Medicine Technology:Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 3Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 4Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 5Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 6Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 7Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 8Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4
... with the ultimate space efficient engineering ... new Topcon Express Lane the perfect ... practice environments: Ultimate Space EfficiencyComplete, ergonomically ... an 8' X 9' room without ...
... who need to move their imaging system from ... solution. The IMAGEnet Portable System features a rugged ... monitor. This portable PC solution can be coupled ... be tailored to your multi-site imaging needs. The ...
... combines the best 32-bit software package (IMAGEnet ... offerings to bring you a fast reliable ... efficient "mid-resolution" package takes advantage of the ... the latest graphics capture technology and a ...
Inquire...
Medicine Products: